Annual Financials for INmune Bio Inc.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
- | - | - | 10,916 | 181,000 | |
Sales Growth |
- | - | - | - | 1,558.12% | |
Cost of Goods Sold (COGS) incl. D&A |
- | - | - | - | - | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
- | - | - | - | - | |
Depreciation |
- | - | - | - | - | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | - | - | - | - | |
Gross Income |
- | - | - | - | - | |
Gross Income Growth |
- | - | - | - | - | |
Gross Profit Margin |
- | - | - | - | - | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
981,480 | 12.44M | 7.76M | 12.24M | 29.33M | |
Research & Development |
435,362 | 1.11M | 3.28M | 5.92M | 20.54M | |
Other SG&A |
546,118 | 11.33M | 4.47M | 6.32M | - | |
SGA Growth |
- | 1,167.48% | -37.65% | 57.80% | 139.68% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
(150,000) | - | - | - | - | |
EBIT after Unusual Expense |
(831,480) | - | - | - | - | |
Non Operating Income/Expense |
(10) | - | - | 128,520 | (1.19M) | |
Non-Operating Interest Income |
- | - | 77,688 | - | - | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | - | - | - | - | |
Interest Expense Growth |
- | - | - | - | - | |
Gross Interest Expense |
- | - | - | - | - | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(831,486) | (12.44M) | (7.68M) | (12.1M) | (30.34M) | |
Pretax Income Growth |
- | -1,396.12% | 38.28% | -57.58% | -150.76% | |
Pretax Margin |
- | - | - | - | -16,762.43% | NA |
Income Tax |
- | - | - | - | - | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(831,486) | (12.44M) | (7.68M) | (12.1M) | (30.34M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(831,486) | (12.44M) | (7.68M) | (12.1M) | (30.34M) | |
Net Income Growth |
- | -1,396.12% | 38.28% | -57.58% | -150.76% | |
Net Margin Growth |
- | - | - | - | -16,762.43% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(831,486) | (12.44M) | (7.68M) | (12.1M) | (30.34M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(831,486) | (12.44M) | (7.68M) | (12.1M) | (30.34M) | |
EPS (Basic) |
(0.07) | (1.28) | (0.75) | (1.01) | (1.88) | |
EPS (Basic) Growth |
- | -1,623.62% | 41.48% | -35.03% | -86.38% | |
Basic Shares Outstanding |
11.22M | 9.74M | 10.27M | 11.99M | 16.13M | |
EPS (Diluted) |
(0.07) | (1.28) | (0.75) | (1.01) | (1.88) | |
EPS (Diluted) Growth |
- | -1,623.62% | 41.48% | -35.03% | -86.38% | |
Diluted Shares Outstanding |
11.22M | 9.74M | 10.27M | 11.99M | 16.13M | |
EBITDA |
- | - | (7.76M) | (12.23M) | (29.15M) | |
EBITDA Growth |
- | - | - | -57.65% | -138.42% | |
EBITDA Margin |
- | - | - | - | -16,106.63% | NA |